Elicio Therapeutics Future Growth

We currently don't have sufficient analyst coverage to forecast growth and revenue for Elicio Therapeutics.

n/a

Earnings growth rate

n/a

EPS growth rate

No updates

Earnings and Revenue Growth Forecasts

DB:9HA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	N/A	-42	-42	2
12/31/2025	N/A	N/A	-41	-41	3
12/31/2024	N/A	N/A	-37	-37	3
9/30/2024	N/A	-47	-38	-38	N/A
6/30/2024	N/A	-39	-36	-36	N/A
3/31/2024	N/A	-39	-37	-37	N/A
12/31/2023	N/A	-35	-33	-33	N/A
9/30/2023	N/A	-33	-30	-30	N/A
6/30/2023	N/A	-29	-30	-30	N/A
3/31/2023	N/A	-29	-25	-25	N/A
12/31/2022	N/A	-28	-23	-22	N/A
9/30/2022	N/A	-28	-22	-21	N/A
3/31/2022	N/A	-27	-24	-23	N/A
12/31/2021	N/A	-26	-24	-24	N/A
3/31/2021	N/A	-19	-20	-20	N/A
12/31/2020	N/A	-16	-17	-17	N/A

Earnings vs Savings Rate: Insufficient data to determine if 9HA's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 9HA's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if 9HA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 9HA's revenue is forecast to grow faster than the German market.

High Growth Revenue: 9HA is forecast to have no revenue next year.

Future ROE: Insufficient data to determine if 9HA's Return on Equity is forecast to be high in 3 years time